Exercise Improves Cognitive Impairment and Dopamine Metabolism in MPTP-Treated Mice
详细信息 查看全文
- 作者：Aderbal S. Aguiar Jr. ; Samantha C. Lopes ; Fabrine S. M. Tristão…
- 关键词：Exercise ; MPTP ; Parkinson’s disease ; Cognition ; Dopamine D2 receptor
- 刊名：Neurotoxicity Research
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：29
- 期：1
- 页码：118-125
- 全文大小：957 KB
- 参考文献：Aguiar AS Jr, Speck AE, Prediger RD, Kapczinski F, Pinho RA (2008) Downhill training upregulates mice hippocampal and striatal brain-derived neurotrophic factor levels. J Neural Transm 115(9):1251–1255. doi:10.1007/s00702-008-0071-2 PubMed CrossRef
Aguiar AS Jr, Castro AA, Moreira EL, Glaser V, Santos AR, Tasca CI, Latini A, Prediger RD (2011) Short bouts of mild-intensity physical exercise improve spatial learning and memory in aging rats: involvement of hippocampal plasticity via AKT, CREB and BDNF signaling. Mech Ageing Dev 132(11–12):560–567. doi:10.1016/j.mad.2011.09.005 PubMed CrossRef
Aguiar AS Jr, Moreira EL, Hoeller AA, Oliveira PA, Cordova FM, Glaser V, Walz R, Cunha RA, Leal RB, Latini A, Prediger RD (2013a) Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice. Neuroscience 243:46–53. doi:10.1016/j.neuroscience.2013.03.039 PubMed CrossRef
Aguiar AS Jr, Tristao FS, Amar M, Chevarin C, Lanfumey L, Mongeau R, Corti O, Prediger RD, Raisman-Vozari R (2013b) Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurotox Res 24(2):280–287. doi:10.1007/s12640-013-9389-0 PubMed CrossRef
Aguiar AS Jr, Tristao FS, Amar M, Chevarin C, Glaser V, de Paula Martins R, Moreira EL, Mongeau R, Lanfumey L, Raisman-Vozari R, Latini A, Prediger RD (2014) Six weeks of voluntary exercise don’t protect C57BL/6 mice against neurotoxicity of MPTP and MPP(+). Neurotox Res 25(2):147–152. doi:10.1007/s12640-013-9412-5 PubMed CrossRef
Aguiar AS Jr, Duzzioni M, Remor AP, Tristao FS, Matheus FC, Raisman-Vozari R, Latini A, Prediger RD (2015) Moderate-intensity physical exercise protects against experimental 6-hydroxydopamine-induced hemiparkinsonism through Nrf2-antioxidant response element pathway. Neurochem Res. doi:10.1007/s11064-015-1709-8 PubMed
Ahmad SO, Park JH, Stenho-Bittel L, Lau YS (2009) Effects of endurance exercise on ventral tegmental area neurons in the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid-treated mice. Neurosci Lett 450(2):102–105. doi:10.1016/j.neulet.2008.11.065 PubMed CrossRef
Al-Jarrah M, Pothakos K, Novikova L, Smirnova IV, Kurz MJ, Stehno-Bittel L, Lau YS (2007) Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration. Neuroscience 149(1):28–37. doi:10.1016/j.neuroscience.2007.07.038 PubMed PubMedCentral CrossRef
Baptista PP, de Senna PN, Paim MF, Saur L, Blank M, do Nascimento P, Ilha J, Vianna MR, Mestriner RG, Achaval M, Xavier LL (2013) Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats. Pharmacol Biochem Behav 104:113–118. doi:10.1016/j.pbb.2012.12.020 PubMed CrossRef
Barbiero JK, Santiago R, Tonin FS, Boschen S, da Silva LM, Werner MFD, da Cunha C, Lima MMS, Vital MABF (2014) PPAR-alpha agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 53:35–44. doi:10.1016/j.pnpbp.2014.02.009 PubMed CrossRef
Bissonnette S, Muratot S, Vernoux N, Bezeau F, Calon F, Hebert SS, Samadi P (2014) The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci 40(2):2406–2416. doi:10.1111/ejn.12596 PubMed CrossRef
Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ (2009) Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson’s disease. Brain 132(Pt 5):1366–1375. doi:10.1093/brain/awn337 PubMed CrossRef
Chefer SI, Kimes AS, Matochik JA, Horti AG, Kurian V, Shumway D, Domino EF, London ED, Mukhin AG (2008) Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology 33(2):270–278. doi:10.1038/sj.npp.1301404 PubMed CrossRef
Colcombe S, Kramer AF (2003) Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci 14(2):125–130PubMed CrossRef
Cooper JR, Bloom FE, Roth RH (2003) Dopamine. In: Cooper JR, Bloom FE, Roth RH (eds) The biochemical basis of Neuropharmacology, 8th edn. Oxford University Press, New York, pp 225–270
Elsinga PH, Hatano K, Ishiwata K (2006) PET tracers for imaging of the dopaminergic system. Curr Med Chem 13(18):2139–2153PubMed CrossRef
Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK, Jakowec MW (2004) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 77(3):378–390. doi:10.1002/jnr.20162 PubMed CrossRef
Fisher BE, Li Q, Nacca A, Salem GJ, Song J, Yip J, Hui JS, Jakowec MW, Petzinger GM (2013) Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson’s disease. NeuroReport 24(10):509–514. doi:10.1097/WNR.0b013e328361dc13 PubMed CrossRef
Foley TE, Fleshner M (2008) Neuroplasticity of dopamine circuits after exercise: implications for central fatigue. Neuromolecular Med 10(2):67–80. doi:10.1007/s12017-008-8032-3 PubMed CrossRef
Frazzitta G, Bertotti G, Morelli M, Riboldazzi G, Pelosin E, Balbi P, Boveri N, Comi C, Turla M, Leva S, Felicetti G, Maestri R (2012) Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation 30(4):295–301. doi:10.3233/NRE-2012-0758 PubMed
Gilliam PE, Spirduso WW, Martin TP, Walters TJ, Wilcox RE, Farrar RP (1984) The effects of exercise training on [3H]-spiperone binding in rat striatum. Pharmacol Biochem Behav 20(6):863–867PubMed CrossRef
Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45(4):489–496. doi:10.1016/j.neuron.2005.01.041 PubMed CrossRef
Graham WC, Crossman AR, Woodruff GN (1990) Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res 514(1):93–102PubMed CrossRef
Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M (2005) CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30(2):339–349. doi:10.1038/sj.npp.1300568 PubMed CrossRef
Kim DS, Szczypka MS, Palmiter RD (2000) Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20(12):4405–4413PubMed
Kim SE, Ko IG, Kim BK, Shin MS, Cho S, Kim CJ, Kim SH, Baek SS, Lee EK, Jee YS (2010) Treadmill exercise prevents aging-induced failure of memory through an increase in neurogenesis and suppression of apoptosis in rat hippocampus. Exp Gerontol 45(5):357–365. doi:10.1016/j.exger.2010.02.005 PubMed CrossRef
Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273(5657):59–61PubMed CrossRef
Lee CS, Sauer H, Bjorklund A (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72(3):641–653PubMed CrossRef
MacRae PG, Spirduso WW, Cartee GD, Farrar RP, Wilcox RE (1987a) Endurance training effects on striatal D2 dopamine receptor binding and striatal dopamine metabolite levels. Neurosci Lett 79(1–2):138–144PubMed CrossRef
MacRae PG, Spirduso WW, Walters TJ, Farrar RP, Wilcox RE (1987b) Endurance training effects on striatal D2 dopamine receptor binding and striatal dopamine metabolites in presenescent older rats. Psychopharmacology 92(2):236–240PubMed CrossRef
Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10(5):377–393. doi:10.1038/nrd3430 PubMed CrossRef
Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H, Aoki S, Akahane A, Iwashita A, Matsuoka N (2007) Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson’s disease and cognition. J Pharmacol Exp Ther 323(2):708–719. doi:10.1124/jpet.107.121962 PubMed CrossRef
Morishima M, Harada N, Hara S, Sano A, Seno H, Takahashi A, Morita Y, Nakaya Y (2006) Monoamine oxidase A activity and norepinephrine level in hippocampus determine hyperwheel running in SPORTS rats. Neuropsychopharmacology 31(12):2627–2638. doi:10.1038/sj.npp.1301028 PubMed CrossRef
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2009) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16(6):653–661. doi:10.1038/nm.2165 CrossRef
Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vuckovic M, Fisher BE, Togasaki DM, Jakowec MW (2007) Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci 27(20):5291–5300. doi:10.1523/JNEUROSCI.1069-07.2007 PubMed CrossRef
Picconi B, Centonze D, Rossi S, Bernardi G, Calabresi P (2004) Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain 127(Pt 7):1661–1669. doi:10.1093/brain/awh190 PubMed CrossRef
Pothakos K, Kurz MJ, Lau YS (2009) Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson’s disease with severe neurodegeneration. BMC Neurosci 10:6. doi:10.1186/1471-2202-10-6 PubMed PubMedCentral CrossRef
Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN (2006) The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson’s disease. Exp Neurol 202(2):391–403. doi:10.1016/j.expneurol.2006.07.001 PubMed CrossRef
Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, Figueiredo CP, Matheus FC, Ginestet L, Chevarin C, Bel ED, Mongeau R, Hamon M, Lanfumey L, Raisman-Vozari R (2010) Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson’s disease. Neurotox Res 17(2):114–129. doi:10.1007/s12640-009-9087-0 PubMed CrossRef
Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R (2011) The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson’s disease. Curr Pharm Des 17(5):489–507PubMed CrossRef
Rinne JO, Laihinen A, Nagren K, Bergman J, Solin O, Haaparanta M, Ruotsalainen U, Rinne UK (1990) PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson’s disease. J Neurosci Res 27(4):494–499. doi:10.1002/jnr.490270409 PubMed CrossRef
Rinne JO, Laihinen A, Lonnberg P, Marjamaki P, Rinne UK (1991) A post-mortem study on striatal dopamine receptors in Parkinson’s disease. Brain Res 556(1):117–122PubMed CrossRef
Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147(1):90–95PubMed CrossRef
Sung YH, Kim SC, Hong HP, Park CY, Shin MS, Kim CJ, Seo JH, Kim DY, Kim DJ, Cho HJ (2012) Treadmill exercise ameliorates dopaminergic neuronal loss through suppressing microglial activation in Parkinson’s disease mice. Life Sci 91(25–26):1309–1316. doi:10.1016/j.lfs.2012.10.003 PubMed CrossRef
Tajiri N, Yasuhara T, Shingo T, Kondo A, Yuan W, Kadota T, Wang F, Baba T, Tayra JT, Morimoto T, Jing M, Kikuchi Y, Kuramoto S, Agari T, Miyoshi Y, Fujino H, Obata F, Takeda I, Furuta T, Date I (2010) Exercise exerts neuroprotective effects on Parkinson’s disease model of rats. Brain Res 1310:200–207. doi:10.1016/j.brainres.2009.10.075 PubMed CrossRef
Tillerson JL, Caudle WM, Reveron ME, Miller GW (2003) Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson’s disease. Neuroscience 119(3):899–911PubMed CrossRef
Toy WA, Petzinger GM, Leyshon BJ, Akopian GK, Walsh JP, Hoffman MV, Vuckovic MG, Jakowec MW (2014) Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease. Neurobiol Dis 63:201–209. doi:10.1016/j.nbd.2013.11.017 PubMed PubMedCentral CrossRef
Vuckovic MG, Li Q, Fisher B, Nacca A, Leahy RM, Walsh JP, Mukherjee J, Williams C, Jakowec MW, Petzinger GM (2010) Exercise elevates dopamine D2 receptor in a mouse model of Parkinson’s disease: in vivo imaging with [(1)(8)F]fallypride. Mov Disord 25(16):2777–2784. doi:10.1002/mds.23407 PubMed PubMedCentral CrossRef - 作者单位：Aderbal S. Aguiar Jr. (1) (2)
Samantha C. Lopes (1)
Fabrine S. M. Tristão (3)
Daniel Rial (1)
Gisele de Oliveira (4)
Cláudio da Cunha (4)
Rita Raisman-Vozari (3)
Rui D. Prediger (2)
1. Departamento de Farmacologia, Universidade Federal de Santa Catarina, Florianópolis, SC, 88040-900, Brazil
2. Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, 88040-900, Brazil
3. INSERM UMR 975 – CNRS UMR 7225, Hôpital de la Salpêtrière—Bâtiment, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Université Pierre et Marie Curie, UPMC, 75651, Paris, France
4. Departamento de Farmacologia, Centro Politécnico, Universidade Federal do Paraná, Curitiba, PR, 81531-980, Brazil - 刊物主题：Neurosciences; Neurology; Neurochemistry; Pharmacology/Toxicology; Neurobiology; Cell Biology;
- 出版者：Springer US
- ISSN：1476-3524
文摘
The classical motor symptoms of Parkinson’s disease (PD) are preceded by non-motor symptoms in preclinical stages, including cognition impairment. The current drug treatment for PD is palliative and does not meet the clinical challenges of the disease, such as levodopa-induced dyskinesia, non-motor symptoms, and neuroprotection. We investigated the neuroprotective and disease-modifying potential of physical exercise in a preclinical animal model of PD. C57BL/6 mice (adult males) ran on a horizontal treadmill for 6 weeks (moderate intensity, 5 times/week) and were treated intranasally with 65 mg/kg of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Exercise did not protect against MPTP-induced nigrostriatal neurodegeneration or frontostriatal dopamine depletion but decreased striatal dopamine turnover. Exercise also attenuated procedural and working memory impairment and D2 receptor hypersensitivity in MPTP-treated mice. In summary, exercise improved dopaminergic neurotransmission and enhanced cognition in a preclinical animal model of PD.